恩度联合吉西他滨及铂类治疗非小细胞肺癌的临床效果及对患者P糖蛋白表达的影响

Analysis of Endostar Plus Gemcitabine and Cisplatin in Patients with Non-small Cell Lung Cancer P Glycoprotein Expression and Clinical Efficacy

目的探讨恩度联合吉西他滨及铂类治疗非小细胞肺癌(NSCLC)的效果及对患者P糖蛋白(P-gp)表达的影响。方法将NSCLC初治患者80例分为2组,其中使用铂类结合吉西他滨及恩度化疗患者38例为观察组,使用铂类结合吉西他滨化疗患者42例为对照组。观察2组患者近期治疗效果、生存状况、不良反应及P-gp定性状况。结果 2组均无CR患者,观察组总有效率为34. 21%,高于对照组的23. 81%,但差异无统计学意义(P> 0. 05);观察组平均生存时间为(17. 25±3. 46)月,高于对照组的(14. 89±3. 16)月,但差异无统计学意义(P> 0. 05); 2组患者在心电图、血液血毒性、胃肠道反应及肝肾功能损伤等不良反应方面对比,差异无统计学意义(P> 0. 05)。治疗后观察组P-gp阳性率为39. 47%,低于对照组的59. 52%,差异有统计学意义(P <0. 05)。结论恩度联合吉西他滨及铂类可一定程度提高晚期NSCLC患者病情缓解率及延长患者生存时间,同时可降低患者P-gp阳性表达率。

Objective To investigate the efficacy of Endo combined with gemcitabine and platinum in the treatment of non-small cell lung cancer( NSCLC) and its effect on the expression of P-glycoprotein( P-gp) in patients. Methods Eighty NSCLC patients were divided into two groups. Among them,38 cases were treated with platinum combined with gemcitabine and Endi chemotherapy,and 42 cases were treated with platinum combined with gemcitabine chemotherapy as control group. Observe the short-term treatment effect,survival status,adverse reactions and qualitative status of P-gp in the two groups of patients. Results There were no patients with CR in both groups. The total effective rate was 34. 21% in the observation group and 23. 81%in the control group,but the difference was not statistically significant( P > 0. 05). The average survival time in the observation group was( 17. 25 ± 3. 46) months. In the control group( 14. 89 ± 3. 16) months,the difference was not statistically significant( P > 0. 05);the patients in the 2 groups were compared in adverse reactions such as electrocardiogram,hematologic toxicity,gastrointestinal reactions,and liver and kidney function impairments. Statistical significance( P > 0. 05). The positive rate of P-gp conversion in the observation group was 39. 47%,which was lower than the 59. 52% in the control group. The difference was statistically significant( P < 0. 05). Conclusion Enodi combined with gemcitabine and platinum can improve the remission rate and prolong survival time of patients with advanced NSCLC to a certain extent,and can reduce the positive rate of P-gp expression in patients.